BJMO - volume 9, issue 1, february 2015
Z. El Ali MD, PhD, D. Van Brummelen MD, P. Wolter MD, S. Rottey MD, PhD, S. Altintas MD, PhD, D. Schallier MD, PhD, P. Debruyne MD, PhD, C. Gennigens MD, PhD, F. Van Aelst MD, S. Sideris MD, T. Gil MD, N. Sirtaine MD, L. D’Hondt MD, PhD, D. Luyten MD, C. Focan MD, PhD, G. Matus MD, M. Rasschaert MD, G. Pelgrims MD, the BSMO Renal Cancer Task Force Group
Almost 30% of patients with renal cell cancer present initially with advanced stage IV disease. In the past decade, the management of the metastatic renal cell cancer has been revolutionised by the knowledge of its molecular biology and development of targets against vascular endothelial growth factor and mammalian target of rapamycin pathways. In this paper we present recommendations based on a thorough review of available guidelines and data from the phase III randomised controlled trials that evaluated new agents in patients with advanced metastatic renal cancer.
(BELG J MED ONCOL 2015;9(1):16–24)